Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Medical Conditions

Diabetes Mellitus
Diabetes Mellitus, Type 2


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2019 Aug 2020

Publications

"Yale JF, Bodholdt U, Catarig AM, Catrina S, Clark A, Ekberg NR, Erhan U, Holmes P, Knudsen ST, Liutkus J, Sathyapalan T, Schultes B, Rudofsky G. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022 Apr;10(2):e002619. doi: 10.1136/bmjdrc-2021-002619."; "35383100"; "Holmes P, Bell HE, Bozkurt K, Catarig AM, Clark A, Machell A, Sathyapalan T. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Ther. 2021 Nov;12(11):2891-2905. doi: 10.1007/s13300-021-01141-8. Epub 2021 Sep 25."; "34562237"

OBSERVATIONAL

Intervention Type : DRUG
Intervention Description : Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.

Intervention Arm Group : Semaglutide;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Novo Nordisk Investigational Site
    Atherstone
    CV9 1EU
  • Novo Nordisk Investigational Site
    Berkshire
    SL2 1HD
  • Novo Nordisk Investigational Site
    Bradford
    BD14 6ES
  • Novo Nordisk Investigational Site
    Brighton
    BN2 3EW
  • Novo Nordisk Investigational Site
    Camberley
    GU16 7UJ
  • Novo Nordisk Investigational Site
    Cambridgeshire
    PE8 6PL
  • Novo Nordisk Investigational Site
    Chiswick
    W4 3JL
  • Novo Nordisk Investigational Site
    Co Durham
    DH9 8AD
  • Novo Nordisk Investigational Site
    Coventry
    CV6 5BG
  • Novo Nordisk Investigational Site
    Darlington
    DL2 1BY
  • Novo Nordisk Investigational Site
    Dudley
    DY1 2HQ
  • Novo Nordisk Investigational Site
    Durham
    DL3 8SQ
  • Novo Nordisk Investigational Site
    Greenisland
    BT38 8TP
  • Novo Nordisk Investigational Site
    Halifax
    HX2 0QL
  • Novo Nordisk Investigational Site
    Hull
    HU3 2RW
  • Novo Nordisk Investigational Site
    Kettering
    NN16 8UZ
  • Novo Nordisk Investigational Site
    Leicestershire
    LE12 6JG
  • Novo Nordisk Investigational Site
    Leicester
    LE3 1HN
  • Novo Nordisk Investigational Site
    Lincs
    LN11 7QU
  • Novo Nordisk Investigational Site
    London
    SW19 2BY
  • Novo Nordisk Investigational Site
    Machester
    M22 4DH
  • Novo Nordisk Investigational Site
    Manchester
    M8 5RB
  • Novo Nordisk Investigational Site
    Merseyside
    CH43 9JW
  • Novo Nordisk Investigational Site
    Nuneaton
    CV10 7DJ
  • Novo Nordisk Investigational Site
    Rayleigh
    SS6 7DY
  • Novo Nordisk Investigational Site
    Rhyl
    LL18 1DA
  • Novo Nordisk Investigational Site
    South Shields
    NE34 6RE
  • Novo Nordisk Investigational Site
    Southampton
    SO30 3JB
  • Novo Nordisk Investigational Site
    Walton on Thames
    Kt12 4HT
  • Novo Nordisk Investigational Site
    Watford
    WD25 7NL
  • Novo Nordisk Investigational Site
    Wellingborough
    NN8 4RW


The study is sponsored by Novo Nordisk A/S





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT03876015
Last updated 15 January 2021

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.